GlassScriptPhysician profile
Edelyne Neas
NPI 1063092401
$4,791.61
in general payments reported to CMS, 2019-2025
26 companies · $1,884 in 2025
The $1,884 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $46.81 · 2023: $1,501 · 2024: $1,360 · 2025: $1,884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,744.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $517.85 | 2024-2025 | Breztri, Airsupra |
| Novo Nordisk INC | $430.76 | 2022-2025 | Wegovy |
| Gilead Sciences, INC. | $345.80 | 2024-2025 | Biktarvy, Epclusa |
| Alnylam Pharmaceuticals INC. | $334.75 | 2023-2024 | Amvuttra, Onpattro |
| Janssen Pharmaceuticals, INC | $292.24 | 2023-2024 | Invega Sustenna, Xarelto |
| Boston Scientific Corporation | $258.07 | 2023 | Watchman Access System, Opticross |
| Biosense Webster, INC. | $256.90 | 2023-2024 | Carto 3 |
| Mannkind Corporation | $250.11 | 2023 | Afrezza |
| Sanofi-Aventis U.S. LLC | $246.95 | 2025 | |
| Abbvie INC. | $228.95 | 2024-2025 | |
| Medicure Pharma INC. | $135.75 | 2025 | Zypitamag |
| Cvrx, INC. | $133.30 | 2024 | Barostim Neo System |
| Glaxosmithkline, LLC. | $124.99 | 2023 | Arexvy |
| Actelion Pharmaceuticals US, INC. | $123.30 | 2023 | Uptravi, Opsumit |
| Axsome Therapeutics, INC. | $122.25 | 2025 | Symbravo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $121.84 | 2025 | Ultomiris |
| Insmed, INC. | $114.64 | 2023 | Arikayce |
| Verona Pharma, INC. | $113.81 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $106.32 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $104.91 | 2023 | Eliquis |
| Bayer Healthcare Pharmaceuticals INC. | $100.00 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.83 | 2023-2025 | Jardiance |
| Coloplast Corp | $82.93 | 2024 | |
| Amarin Pharma, INC. | $69.83 | 2024 | |
| Mylan Specialty L.P. | $49.07 | 2024 | Yupelri |
| Janssen Biotech, INC. | $31.46 | 2025 | Rybrevant, Carvykti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edelyne Neas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.